International Journal of Hematology

, Volume 89, Issue 1, pp 106–112

Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma

  • Yi Niu
  • Yuankai Shi
  • Shengyu Zhou
  • Feng Pan
  • Shikai Wu
  • Peng Liu
  • Jiangliang Yang
  • Xiaohong Han
  • Xiaohui He
Original Article

DOI: 10.1007/s12185-008-0217-x

Cite this article as:
Niu, Y., Shi, Y., Zhou, S. et al. Int J Hematol (2009) 89: 106. doi:10.1007/s12185-008-0217-x
  • 49 Views

Abstract

The aim and objective of the study is to compare the efficacy of conditioning regimens with or without high-dose radiotherapy for treating aggressive non-Hodgkin’s lymphoma (NHL). Eighty-nine aggressive NHL patients who underwent high-dose therapy in combination with autologous stem cell transplantation (HDT/ASCT) between 1993 and 2006 were retrospectively studied. HDT was either high-dose chemotherapy alone (CT) or high-dose chemoradiotherapy (CRT). Overall, 37 patients in CT group and 52 in CRT group. The median radiotherapy DT in CRT group was 8 Gy. The median count of reinfused CD34+ cells was 6.26 × 106 and 22.16 × 106 cells/kg, respectively (p < 0.001). The median time of leukocyte engraftment was 11 days in CT group and 13 days in CRT group (p = 0.003), and the median platelet engraftment time was 12 days in CT group and 11 days in CRT group (p = 0.305). The median event-free survival (EFS) was 102 and 84 months in CT and CRT groups, respectively (p = 0.783), and the median overall survival (OS) was 102 and 121 months in CT and CRT groups, respectively (p = 0.857). Prolonged hospitalization favored EFS (p = 0.013) and OS (p = 0.011). In conclusion, when compared with CT, high-dose CRT does not improve prognosis.

Keywords

High-dose therapy in combination with autologous stem-cell transplantationAggressive non-Hodgkin’s lymphomaConditioning regimenRadiotherapy

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Yi Niu
    • 1
  • Yuankai Shi
    • 1
  • Shengyu Zhou
    • 1
  • Feng Pan
    • 1
  • Shikai Wu
    • 1
  • Peng Liu
    • 1
  • Jiangliang Yang
    • 1
  • Xiaohong Han
    • 1
  • Xiaohui He
    • 1
  1. 1.Department of Medical Oncology, Cancer Institute (Hospital)Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina